Review of the emerging treatment of clostridium difficile infection with fecal microbiota transplantation and insights into future challenges

Clinics in Laboratory Medicine

Volumn 34, Issue 4, 2014, Pages 787-798

  Kassam, Zain ^a   Lee, Christine H ^b,c   Hunt, Richard H ^d,e  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^d MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^e HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Clostridium difficile; Fecal microbiota transplantation; Health care associated infections; Treatment

Indexed keywords

ENEMA; VANCOMYCIN;

BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; DRUG DOSE REDUCTION; ENCAPSULATION; FECAL MICROBIOTA TRANSPLANTATION; FREEZE THAWING; FREEZING; HUMAN; NASOGASTRIC TUBE; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84923918647     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.08.007     Document Type: Review

References (67)

1. Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. NEngl J Med 2014, 370(13):1198-1208.
2. Collins C., Ayturk M., Flahive J. Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries. JAm Coll Surg 2014, 218(6):1141-1148.
3. Zilberberg M., Shorr A., Kollef M. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008, 14(6):929-931.
4. Gravel D., Miller M., Simor A., et al. Health care' associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis 2009, 48(5):568-576. 10.1086/596703.
5. Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377(9759):63-73. 10.1016/S0140-6736(10)61266-4.
6. Simango C., Uladi S. Detection of Clostridium difficile diarrhoea in Harare, Zimbabwe. Trans R Soc Trop Med Hyg 2014, 108(6):354-357. 10.1093/trstmh/tru042.
7. Wiegand P.N., Nathwani D., Wilcox M.H., et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of health care-facility-acquired infection. JHosp Infect 2012, 81(1):1-14. 10.1016/j.jhin.2012.02.004.
8. McGlone S., Bailey R., Zimmer S. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012, 18(3):282-289. 10.1111/j.1469-0691.2011.03571.x.
9. Dubberke E., Olsen M. Burden of Clostridium difficile on the health care system. Clin Infect Dis 2012, 55(Suppl 2):S88-S92. 10.1093/cid/cis335.
10. Vonberg R., Reichardt C., Behnke M. Cost of nosocomial Clostridium difficile-associated diarrhoea. JHosp Infect 2008, 70:15-20.
11. Kelly C.P., Lamont J.T. Clostridium difficile - more difficult than ever. NEngl J Med 2008, 359:1932-1940.
12. Lynch T., Chong P., Zhang J., et al. Characterization of a stable, metronidazole-resistant clostridium difficile clinical isolate. PLoS One 2013, 8(1):e53757. 10.1371/journal.pone.0053757.
13. Baines S.D., O'Connor R., Freeman J., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. JAntimicrob Chemother 2008, 62(5):1046-1052. 10.1093/jac/dkn313.
14. Peláez T., Alcalá L., Alonso R., et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46(6):1647-1650. 10.1128/AAC.46.6.1647.
15. O'Horo J.C., Jindai K., Kunzer B., et al. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014, 42(1):43-59. 10.1007/s15010-013-0496-x.
16. Petrella L.A., Sambol S.P., Cheknis A., et al. Decreased cure and increased recurrence rates for clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012, 55(3):351-357. 10.1093/cid/cis430.
17. Barbut F., Richard A., Hamadi K. Epidemiology of recurrences or reinfections of Clostridium difficile epidemiology of recurrences or reinfections of Clostridium difficile -associated diarrhea. JClin Microbiol 2000, 38(6):2386-2388.
18. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEngl J Med 2011, 364(5):422-431.
19. Pépin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41(9):1254-1260.
20. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97(7):1769-1775.
21. Song Y., Garg S., Girotra M., et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One 2013, 8(11):e81330. 10.1371/journal.pone.0081330.
22. Chang J.Y., Antonopoulos D.A., Kalra A., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. JInfect Dis 2008, 197(3):435-438. 10.1086/525047.
23. Khoruts A., Dicksved J., Jansson J.K., et al. Khoruts 2010. JClin Gastroenterol 2010, 44(5):354-360.
24. Zhang F., Luo W., Shi Y., et al. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012, 107(11):1755. [author reply: 1755-6]. 10.1038/ajg.2012.251.
25. Kassam Z., Lee C.H., Yuan Y., et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013, 108(4):500-508. 10.1038/ajg.2013.59.
26. Guo B., Harstall C., Louie T., et al. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012, 35(8):865-875. 10.1111/j.1365-2036.2012.05033.x.
27. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection. Clin Infect Dis 2011, 53(10):994-1002. 10.1093/cid/cir632.
28. Sha S., Liang J., Chen M., et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014, 39(10):1003-1032. 10.1111/apt.12699.
29. Smith M.B., Kelly C., Alm E.J. How to regulate faecal transplants. Nature 2014, 506:290-291.
30. Moayyedi P., Marshall J.K., Yuan Y., et al. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol 2014, 28(2):1-3.
31. Kassam Z., Murray T.S. Navigating the pediatric microbiome: emerging evidence and clinical implications. Curr Pediatr Rep 2014, 2(2):93-101. 10.1007/s40124-014-0040-1.
32. Van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEngl J Med 2013, 368(5):407-415. 10.1056/NEJMoa1205037.
33. Youngster I., Sauk J., Pindar C., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014, 58(11):1-8. 10.1093/cid/ciu135.
34. Konijeti G.G., Sauk J., Shrime M.G., et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014, 58(11):1-8. 10.1093/cid/ciu128.
35. Kassam Z., Hundal R., Marshall J., et al. Fecal transplant via retention enema for refractory or recurrent clostridium difficile infection. Arch Intern Med 2012, 172(2):2012-2014.
36. Mattila E., Uusitalo-Seppälä R., Wuorela M., et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012, 142(3):490-496. 10.1053/j.gastro.2011.11.037.
37. Kelly C.R., Ihunnah C., Fischer M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014, 109(7):1065-1071. 10.1038/ajg.2014.133.
38. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for health care epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455. 10.1086/651706.
39. Surawicz C.M., Brandt L.J., Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013, 108(4):478-498. [quiz: 499]. 10.1038/ajg.2013.4.
40. Debast S.B., Bauer M.P., Kuijper E.J. Comm. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014, 20(2):1-26.
41. Bakken J.S., Borody T., Brandt L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9(12):1044-1049. 10.1016/j.cgh.2011.08.014.
42. Allen-Vercoe E., Reid G., Viner N., et al. ACanadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 2012, 26(7):457-462.
43. Lee C.H., Belanger J.E., Kassam Z., et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis 2014, 33:1425-1428. 10.1007/s10096-014-2088-9.
44. Collins S.M., Kassam Z., Bercik P. The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Curr Opin Microbiol 2013, 16(3):240-245.
45. Schwartz M., Gluck M., Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013, 108(8):1367. 10.1038/ajg.2013.164.
46. Brandt L.J., Aroniadis O.C., Mellow M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107(7):1079-1087. 10.1038/ajg.2012.60.
47. Kassam Z., Lee C.H., Yuan Y., et al. Navigating long-term safety in fecal microbiota transplantation. Am J Gastroenterol 2013, 108(9):1538. 10.1038/ajg.2013.214.
48. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36(5):580-585. 10.1086/367657.
49. Silverman M.S., Davis I., Pillai D.R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010, 8(5):471-473. 10.1016/j.cgh.2010.01.007.
50. Yoon S.S., Brandt L.J. Treatment of refractory/recurrent C. difficile- associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. JClin Gastroenterol 2010, 44(8):562-566.
51. Kelly C.R., de Leon L., Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. JClin Gastroenterol 2012, 46(2):145-149. 10.1097/MCG.0b013e318234570b.
52. Borody T.J., Warren E.F., Leis S.M., et al. Bacteriotherapy using fecal flora. JClin Gastroenterol 2004, 38(6):475-483. 10.1097/01.mcg.0000128988.13808.dc.
53. Lund-Tønnesen S., Berstad A., Schreiner A., et al. Clostridium difficile-associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen 1998, 118(17):1027-1030.
54. Hamilton M.J., Weingarden A.R., Sadowsky M.J., et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107(5):761-767. 10.1038/ajg.2011.482.
55. Garborg K., Waagsbø B., Stallemo A., et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010, 42(11-12):857-861. 10.3109/00365548.2010.499541.
56. Schwan A., Sjolin S., Trottestam U., et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet 1983, 2(8354):845.
57. Petrof E.O., Gloor G.B., Vanner S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "RePOOPulating" the gut. Microbiome 2013, 1(1):3. 10.1186/2049-2618-1-3.
58. Louie T, Cannon K, O'Grady H, etal. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). Abstract presented at The ID Week Conference. 2014.
59. Kelly C. Fecal transplant for relapsing C. Difficile infection. 2014. U.S. National Institutes of Health Trial Register. NCT Number 01703494. Available at: . Accessed July 14, 2014. http://www.clinicaltrials.gov/ct2/show/NCT01703494?term=fecal+transplant%20%26%20rank=4.
60. Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection in adults and children using a frozen encapsulated inoculum. 2014. U.S. National Institutes of Health Trial Register. NCT Number NCT01914731. Available at: . Accessed July 14, 2014. http://clinicaltrials.gov/ct2/show/NCT01914731?term=fecal%26rank=17.
61. Lee C. Multi-centre trial of fresh vs frozen-and-thawed HBT (fecal transplant) for recurrent CDI. 2014. Available at: U.S. National Institutes of Health Trial Register. NCT Number 01398969. Available at: . Accessed July 14, 2014. http://www.clinicaltrials.gov/ct2/show/NCT01398969?term=fecal+transplant%20%26%20rank=2.
62. Hota S. Oral vancomycin followed by fecal transplant vs. tapering oral vancomycin. 2014. U.S. National Institutes of Health Trial Register. NCT Number 01226992. Available at: . Accessed July 12, 2014. http://www.clinicaltrials.gov/ct2/show/NCT01226992?term=feca%20l+transplant%20%26%20rank=1.
63. Gisser J. Fecal transplant for pediatric patients who have recurrent C-diff infection (FMT). 2014. Available at: U.S. National Institutes of Health Trial Register. NCT Number NCT02134392. Available at: . Accessed July 12, 2014. http://clinicaltrials.gov/ct2/show/NCT02134392?term=gisser%26rank=1.
64. Lawley T.D., Clare S., Walker A.W., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8(10):e1002995. 10.1371/journal.ppat.1002995.
65. Merenstein D., El-Nachef N., Lynch S. Fecal microbial therapy - promises and pitfalls. JPediatr Gastroenterol Nutr 2014, 10.1097/MPG.000000000000415.
66. Smith M, Kassam Z, Edelstein C, etal. OpenBiome. 2014. Available at: . Accessed July, 2014. http://www.openbiome.org/.
67. FDA. Vaccine and Related Biological Product Guidances - draft guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. 2014. Available at: . Accessed September 18, 2014. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm387023.htm?source=govdelivery%26utm_medium=email%26utm_source=govdelivery.